FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study

Lale Kostakoglu, Andre Goy, Giovanni Martinelli, Dolores Caballero, Michael Crump, Gianluca Gaidano, Tara Baetz, Rena Buckstein, Gregg Fine, Guenter Fingerle-Rowson, Claude Berge, Deniz Sahin, Oliver Press, Laurie Sehn

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

An exploratory analysis of 75 follicular lymphoma patients treated with obinutuzumab or rituximab induction therapy (IT) for 4 weeks in the phase II GAUSS study aimed to determine whether positron emission tomography (PET) results could predict progression-free survival (PFS) and tumor response. The proportion of patients with a PFS event (progression or death) was higher in those who were PET-positive after IT (assessed using Deauville five-point scale criteria; 35/52, 67%) than PET-negative (5/20, 25%); the hazard ratio for progression or death was 0.25 (95%CI: 0.01–0.64; p = 0.0018). A significant association was also found when PET results were assessed using International Harmonization Project and European Organisation for Research and Treatment of Cancer criteria. Change between baseline and end of IT in values of standardized uptake value and other PET parameters were associated with PFS and response. Validation of these results in prospective studies of larger cohorts is warranted.

Original languageEnglish
Pages (from-to)372-381
Number of pages10
JournalLeukemia and Lymphoma
Volume58
Issue number2
DOIs
Publication statusPublished - Feb 1 2017

Fingerprint

Follicular Lymphoma
Positron-Emission Tomography
Disease-Free Survival
Therapeutics
Prospective Studies
Neoplasms

Keywords

  • FDG PET/CT
  • follicular lymphoma
  • prediction of response
  • relapse

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma : exploratory analysis of the GAUSS study. / Kostakoglu, Lale; Goy, Andre; Martinelli, Giovanni; Caballero, Dolores; Crump, Michael; Gaidano, Gianluca; Baetz, Tara; Buckstein, Rena; Fine, Gregg; Fingerle-Rowson, Guenter; Berge, Claude; Sahin, Deniz; Press, Oliver; Sehn, Laurie.

In: Leukemia and Lymphoma, Vol. 58, No. 2, 01.02.2017, p. 372-381.

Research output: Contribution to journalArticle

Kostakoglu, L, Goy, A, Martinelli, G, Caballero, D, Crump, M, Gaidano, G, Baetz, T, Buckstein, R, Fine, G, Fingerle-Rowson, G, Berge, C, Sahin, D, Press, O & Sehn, L 2017, 'FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study', Leukemia and Lymphoma, vol. 58, no. 2, pp. 372-381. https://doi.org/10.1080/10428194.2016.1196815
Kostakoglu, Lale ; Goy, Andre ; Martinelli, Giovanni ; Caballero, Dolores ; Crump, Michael ; Gaidano, Gianluca ; Baetz, Tara ; Buckstein, Rena ; Fine, Gregg ; Fingerle-Rowson, Guenter ; Berge, Claude ; Sahin, Deniz ; Press, Oliver ; Sehn, Laurie. / FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma : exploratory analysis of the GAUSS study. In: Leukemia and Lymphoma. 2017 ; Vol. 58, No. 2. pp. 372-381.
@article{c71b72efdeb94e6aa98c68d9e207dc92,
title = "FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study",
abstract = "An exploratory analysis of 75 follicular lymphoma patients treated with obinutuzumab or rituximab induction therapy (IT) for 4 weeks in the phase II GAUSS study aimed to determine whether positron emission tomography (PET) results could predict progression-free survival (PFS) and tumor response. The proportion of patients with a PFS event (progression or death) was higher in those who were PET-positive after IT (assessed using Deauville five-point scale criteria; 35/52, 67{\%}) than PET-negative (5/20, 25{\%}); the hazard ratio for progression or death was 0.25 (95{\%}CI: 0.01–0.64; p = 0.0018). A significant association was also found when PET results were assessed using International Harmonization Project and European Organisation for Research and Treatment of Cancer criteria. Change between baseline and end of IT in values of standardized uptake value and other PET parameters were associated with PFS and response. Validation of these results in prospective studies of larger cohorts is warranted.",
keywords = "FDG PET/CT, follicular lymphoma, prediction of response, relapse",
author = "Lale Kostakoglu and Andre Goy and Giovanni Martinelli and Dolores Caballero and Michael Crump and Gianluca Gaidano and Tara Baetz and Rena Buckstein and Gregg Fine and Guenter Fingerle-Rowson and Claude Berge and Deniz Sahin and Oliver Press and Laurie Sehn",
year = "2017",
month = "2",
day = "1",
doi = "10.1080/10428194.2016.1196815",
language = "English",
volume = "58",
pages = "372--381",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor and Francis Ltd.",
number = "2",

}

TY - JOUR

T1 - FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma

T2 - exploratory analysis of the GAUSS study

AU - Kostakoglu, Lale

AU - Goy, Andre

AU - Martinelli, Giovanni

AU - Caballero, Dolores

AU - Crump, Michael

AU - Gaidano, Gianluca

AU - Baetz, Tara

AU - Buckstein, Rena

AU - Fine, Gregg

AU - Fingerle-Rowson, Guenter

AU - Berge, Claude

AU - Sahin, Deniz

AU - Press, Oliver

AU - Sehn, Laurie

PY - 2017/2/1

Y1 - 2017/2/1

N2 - An exploratory analysis of 75 follicular lymphoma patients treated with obinutuzumab or rituximab induction therapy (IT) for 4 weeks in the phase II GAUSS study aimed to determine whether positron emission tomography (PET) results could predict progression-free survival (PFS) and tumor response. The proportion of patients with a PFS event (progression or death) was higher in those who were PET-positive after IT (assessed using Deauville five-point scale criteria; 35/52, 67%) than PET-negative (5/20, 25%); the hazard ratio for progression or death was 0.25 (95%CI: 0.01–0.64; p = 0.0018). A significant association was also found when PET results were assessed using International Harmonization Project and European Organisation for Research and Treatment of Cancer criteria. Change between baseline and end of IT in values of standardized uptake value and other PET parameters were associated with PFS and response. Validation of these results in prospective studies of larger cohorts is warranted.

AB - An exploratory analysis of 75 follicular lymphoma patients treated with obinutuzumab or rituximab induction therapy (IT) for 4 weeks in the phase II GAUSS study aimed to determine whether positron emission tomography (PET) results could predict progression-free survival (PFS) and tumor response. The proportion of patients with a PFS event (progression or death) was higher in those who were PET-positive after IT (assessed using Deauville five-point scale criteria; 35/52, 67%) than PET-negative (5/20, 25%); the hazard ratio for progression or death was 0.25 (95%CI: 0.01–0.64; p = 0.0018). A significant association was also found when PET results were assessed using International Harmonization Project and European Organisation for Research and Treatment of Cancer criteria. Change between baseline and end of IT in values of standardized uptake value and other PET parameters were associated with PFS and response. Validation of these results in prospective studies of larger cohorts is warranted.

KW - FDG PET/CT

KW - follicular lymphoma

KW - prediction of response

KW - relapse

UR - http://www.scopus.com/inward/record.url?scp=84995587989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995587989&partnerID=8YFLogxK

U2 - 10.1080/10428194.2016.1196815

DO - 10.1080/10428194.2016.1196815

M3 - Article

AN - SCOPUS:84995587989

VL - 58

SP - 372

EP - 381

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 2

ER -